TY - JOUR
T1 - Association of candidate pharmacogenetic markers with platinum-induced ototoxicity
T2 - PanCareLIFE dataset
AU - PanCareLIFE Consortium
AU - Langer, Thorsten
AU - Clemens, Eva
AU - Broer, Linda
AU - Maier, Lara
AU - Uitterlinden, André G
AU - de Vries, Andrica C H
AU - van Grotel, Martine
AU - Pluijm, Saskia F M
AU - Binder, Harald
AU - Mayer, Benjamin
AU - von dem Knesebeck, Annika
AU - Byrne, Julianne
AU - van Dulmen-den Broeder, Eline
AU - Crocco, Marco
AU - Grabow, Desiree
AU - Kaatsch, Peter
AU - Kaiser, Melanie
AU - Spix, Claudia
AU - Kenborg, Line
AU - Winther, Jeanette F
AU - Rechnitzer, Catherine
AU - Hasle, Henrik
AU - Kepak, Tomas
AU - van der Kooi, Anne-Lotte F
AU - Kremer, Leontien C
AU - Kruseova, Jarmila
AU - Bielack, Stefan
AU - Sorg, Benjamin
AU - Hecker-Nolting, Stefanie
AU - Kuehni, Claudia E
AU - Ansari, Marc
AU - Kompis, Martin
AU - van der Pal, Heleen J
AU - Parfitt, Ross
AU - Deuster, Dirk
AU - Matulat, Peter
AU - Tillmanns, Amelie
AU - Tissing, Wim J E
AU - Beck, Jörn D
AU - Elsner, Susanne
AU - Am Zehnhoff-Dinnesen, Antoinette
AU - van den Heuvel-Eibrink, Marry M
AU - Zolk, Oliver
N1 - © 2020 The Authors.
PY - 2020/10
Y1 - 2020/10
N2 - Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patients were assigned to three phenotype categories: no, minor, and clinically relevant hearing loss. Fourteen variants in eleven candidate genes (ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, SOD2, WFS1, and ACYP2) were genotyped. The genotype and phenotype data represent a resource for conducting meta-analyses to derive a more precise pooled estimate of the effects of genes on the risk of hearing loss due to platinum treatment.
AB - Genetic association studies suggest a genetic predisposition for cisplatin-induced ototoxicity. Among other candidate genes, thiopurine methyltransferase (TPMT) is considered a critical gene for susceptibility to cisplatin-induced hearing loss in a pharmacogenetic guideline. The PanCareLIFE cross-sectional cohort study evaluated the genetic associations in a large pan-European population and assessed the diagnostic accuracy of the genetic markers. 1,112 pediatric cancer survivors who had provided biomaterial for genotyping were screened for participation in the pharmacogenetic association study. 900 participants qualified for inclusion. Based on the assessment of original audiograms, patients were assigned to three phenotype categories: no, minor, and clinically relevant hearing loss. Fourteen variants in eleven candidate genes (ABCC3, OTOS, TPMT, SLC22A2, NFE2L2, SLC16A5, LRP2, GSTP1, SOD2, WFS1, and ACYP2) were genotyped. The genotype and phenotype data represent a resource for conducting meta-analyses to derive a more precise pooled estimate of the effects of genes on the risk of hearing loss due to platinum treatment.
KW - Adverse drug reaction
KW - Cancer survivors
KW - Childhood cancer
KW - Cisplatin: carboplatin
KW - Drug-induced ototoxicity
KW - Genetic markers
KW - Multicenter cohort study
KW - Pharmacogenetics
UR - http://www.scopus.com/inward/record.url?scp=85090055900&partnerID=8YFLogxK
U2 - 10.1016/j.dib.2020.106227
DO - 10.1016/j.dib.2020.106227
M3 - Article
C2 - 32939381
SN - 2352-3409
VL - 32
SP - 106227
JO - Data in brief
JF - Data in brief
M1 - 106227
ER -